

ROCKWELL MEDICAL, INC.

Form 8-K

January 27, 2015

**UNITED STATES**

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 26, 2015

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Michigan                      000-23661      38-3317208  
(State or other jurisdiction   (Commission   (IRS Employer  
of incorporation)              File Number) Identification No.)

30142 Wixom Road, Wixom, Michigan 48393  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (248) 960-9009

Not applicable

(Former name or former address, if changed since last report)

Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On January 26, 2015, Rockwell Medical, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) approved Triferic™ for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease. A copy of the press release is filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibit is filed with this Form 8-K:

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release dated January 26, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROCKWELL MEDICAL, INC.

January 26, 2015 By: /S/ Thomas E. Klema  
Thomas E. Klema  
Its: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release dated January 26, 2015.